CN104398677A - Compound composition of tartary buckwheat general flavone and gynostemma pentaphylla total saponin - Google Patents
Compound composition of tartary buckwheat general flavone and gynostemma pentaphylla total saponin Download PDFInfo
- Publication number
- CN104398677A CN104398677A CN201410626969.XA CN201410626969A CN104398677A CN 104398677 A CN104398677 A CN 104398677A CN 201410626969 A CN201410626969 A CN 201410626969A CN 104398677 A CN104398677 A CN 104398677A
- Authority
- CN
- China
- Prior art keywords
- radix
- extracting solution
- rhizoma fagopyri
- fagopyri tatarici
- gynostemma pentaphyllum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006509 Gynostemma pentaphyllum Species 0.000 title claims abstract description 41
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 title claims abstract description 41
- 229930003944 flavone Natural products 0.000 title claims abstract description 36
- 235000011949 flavones Nutrition 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 22
- 239000000203 mixture Substances 0.000 title abstract description 20
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title abstract description 7
- 150000002212 flavone derivatives Chemical class 0.000 title abstract description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title abstract description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 title abstract description 5
- 229930182490 saponin Natural products 0.000 title abstract description 5
- 150000007949 saponins Chemical class 0.000 title abstract description 5
- 244000130270 Fagopyrum tataricum Species 0.000 title abstract 3
- 235000014693 Fagopyrum tataricum Nutrition 0.000 title abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940046009 vitamin E Drugs 0.000 claims abstract description 6
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 6
- 239000011709 vitamin E Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 75
- 229930003935 flavonoid Natural products 0.000 claims description 35
- 150000002215 flavonoids Chemical class 0.000 claims description 35
- 235000017173 flavonoids Nutrition 0.000 claims description 35
- 150000002213 flavones Chemical class 0.000 claims description 29
- 239000011347 resin Substances 0.000 claims description 29
- 229920005989 resin Polymers 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 238000010438 heat treatment Methods 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 14
- 239000012043 crude product Substances 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 10
- 230000008025 crystallization Effects 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 230000000274 adsorptive effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 238000005202 decontamination Methods 0.000 claims description 5
- 230000003588 decontaminative effect Effects 0.000 claims description 5
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 238000011010 flushing procedure Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 8
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 6
- 230000002107 myocardial effect Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 4
- 208000031225 myocardial ischemia Diseases 0.000 abstract description 4
- 210000004165 myocardium Anatomy 0.000 abstract description 4
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 7
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 7
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 7
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 7
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 7
- 235000005493 rutin Nutrition 0.000 description 7
- 229960004555 rutoside Drugs 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229930187479 gypenoside Natural products 0.000 description 5
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 229940093797 bioflavonoids Drugs 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000036449 good health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- BWORNNDZQGOKBY-UHFFFAOYSA-N ombuin Chemical compound C=1C(OC)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(OC)C(O)=C1 BWORNNDZQGOKBY-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 1
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 description 1
- VNUGYONVKHBAOG-UHFFFAOYSA-N Gypenoside I Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC2C(C3C(C4C(C5(CCC(C5C(O)C4)C(C)(CCC=C(C)C)OC4C(C(O)C(O)C(COC5C(C(O)C(O)C(CO)O5)O)O4)O)C)(C)CC3)(C)CC2)(C)C)O1 VNUGYONVKHBAOG-UHFFFAOYSA-N 0.000 description 1
- 206010021929 Infertility male Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- YQKCHRBAJSATCG-UHFFFAOYSA-N UNPD30744 Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC(C)(CCC=C(C)C)C2C3C(C4(CCC5C(C)(C)C(OC6C(C(O)C(O)C(CO)O6)OC6C(C(O)C(O)C(CO)O6)O)CCC5(C)C4CC3O)C)(C)CC2)O1 YQKCHRBAJSATCG-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- NODILNFGTFIURN-USYOXQFSSA-N ginsenoside Rb3 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-USYOXQFSSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- UVBLDLGZDSGCSN-UHFFFAOYSA-N ginsenoside-Rb3 Natural products C1=CC2C3(C)CCC(O)C(C)(C)C3CCC2(C)C2(C)CCC34CCC(C)C(C)C4C21OC3=O UVBLDLGZDSGCSN-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a compound composition of tartary buckwheat general flavone and gynostemma pentaphylla total saponin. The composition is composed of the following components in parts by weight: 1 to 2 parts of tartary buckwheat general flavone, 2 to 4 parts of gynostemma pentaphylla total saponin, 1 to 3 parts of vitamin E, and 10 to 20 parts of auxiliary materials. The obtained compound composition has a good healthcare and curative effect on patients of cardiovascular diseases and diabetes, and is capable of prominently reducing blood fat and blood sugar. The provided composition has a synergetic effect, thus the curative effect can be prominently improved, and the composition has functions of relieving myocardial ischemia, improving myocardial metabolism, nourishing the myocardium, protecting the myocardial cells, and improving the antioxidant performance of myocardium. The composition has the advantages of better curative effect and no side effect.
Description
Technical field
The invention belongs to food and field of pharmaceutical technology, specifically relate to a kind of Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound.
Background technology
Cardiovascular disease causes the primary disease of our people's death, shows according to the Epidemiological study nineties of 20th century, and such mortality accounts for 37.16% and 26.33% of disease general mortality rate respectively at China's Urban and rural area.Estimate also will rise in the prevalence of 10 ~ 20 Nian Zhong China cardiovascular disease in future and mortality rate.Chinese medicine shows obvious advantage and feature in the treatment of myocardial ischemia in recent years.
Radix Et Rhizoma Fagopyri Tatarici is the crop uniquely integrating seven major nutrient in cereal crops, and its seven major nutrient comprises: 1) bioflavonoids, 2) trace element and mineral, 3) starch, 4) vitamin, 5) cellulose, 6) fat, 7) protein.Wherein, the Main Ingredients and Appearance of bioflavonoids is rutin, has another name called Citrin.Its primary efficacy is: vessel softening, improves microcirculation, heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, removing toxic substances and promoting tissue regeneration, has blood sugar lowering, glucose in urine, blood fat, QI invigorating to refresh oneself, strengthens insulin peripheral action.And rutin does not almost have in other corn.In addition, Radix Et Rhizoma Fagopyri Tatarici is also containing the chlorophyll that other cereal crops do not possess.
Herb Gynostemmae Pentaphylli total glycosides about has more than 80 to plant, wherein 78 kinds of respectively called after gypenoside I ~ LXXV III, wherein some is respectively ginsenoside Rb1, Rb3, Rd, and panoxadiol, 2 Alpha-hydroxy panoxadiol, 2 α, 19-dihydroxy-12-deoxidation panoxadiol etc.Therefore, the assay of its composition and finished product standard, also all using the number of ginsenoside Rb1 as standard.Another containing standard sclerutin class, bessisterol, ombuin etc.
Why " mystery " is because its ginsenoside's constituents (84 kinds) exceedes the several times of Radix Ginseng to gypenoside (gypenoside), it is to cardiovascular disease such as treatment and prophylaxis of hypertension, diabetes, constipation, gypenoside hemorrhoid, asthma, migraine, acne, the symptoms such as mottle have remarkable efficacy, and have comparatively significantly calm, hypnosis, allaying tiredness, appetite stimulator, antidotal effect, to tumor, hepatitis, gastritis, gastric and duodenal ulcers, gastroptosis, stomatitis, coronary heart disease, arteriosclerosis, cholelithiasis, numb limbs and tense tendons, pachylosis, male sterility, sexual disorder, fat and poliosis is bald etc. has better curative effect.Gypenoside (gypenoside) also may become the major physiological active substance that the 21 century mankind conquer cardiovascular disease, diabetes, catatonia, cancer and acquired immune deficiency syndrome (AIDS).
Utilize modern crafts to extract the effective site of two taste medicines, by the extracting method of uniqueness, unique formula, good effect is produced to i.e. trencherman.
Summary of the invention
For improving the activity of Gynostemma Pentaphyllum and Radix Et Rhizoma Fagopyri Tatarici total flavonoids Cardiovarscular, the invention provides a kind of Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound, making the two synergism have good curative effect to cardiovascular disease.
The present invention is realized by following technical proposal: a kind of Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound, be made up of the component of following masses part:
Radix Et Rhizoma Fagopyri Tatarici total flavonoids 1 ~ 2 part,
Gynostemma Pentaphyllum 2 ~ 4 parts,
Vitamin E 1 ~ 3 part,
Adjuvant 10 ~ 20 parts.
Described adjuvant forms by the component of following mass parts:
Starch 40 ~ 50 parts,
Microcrystalline Cellulose 10 ~ 15 parts,
Magnesium stearate 0.5 ~ 1 part.
Above-mentioned Radix Et Rhizoma Fagopyri Tatarici total flavonoids, Gynostemma Pentaphyllum fully mix in proportion, then add pharmaceutically acceptable adjuvant and be prepared into the conventional oral formulations of any one, as capsule, granule, oral liquid, pill or tablet.
Described Radix Et Rhizoma Fagopyri Tatarici total flavonoids is obtained by following each step:
(1) bran of Radix Et Rhizoma Fagopyri Tatarici being added 5 ~ 8 volumes concentration is doubly that the ethanol of 45 ~ 55v/v% carries out heating and refluxing extraction 2 ~ 4 hours, leaches extracting solution I; In residue, add 4 ~ 6 volumes concentration doubly is again that the ethanol of 30 ~ 35v/v% carries out heating and refluxing extraction 1 ~ 3 hour, leaches extracting solution II; In residue, add 4 ~ 7 quality water doubly again carry out heating and refluxing extraction 0.5 ~ 1.5 hour, leach extracting solution III; Merge extractive liquid, I and extracting solution II obtain extracting solution IV;
(2) by step (1) gained extracting solution IV and extracting solution III filtered while hot respectively, gained filtrate often pushes back receipts ethanol respectively, then places partial crystallization after concentrating respectively, leaches crystal and namely obtains Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product;
(3) in step (2) gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product, the ethanol that concentration is 80v/v% is added, be heated to boiling again, keep micro-to boil 1 ~ 3 minute, then filter while hot, then filtrate is placed partial crystallization, until precipitation total flavones, then with deionized water or pure water total flavones, to eluate color close to time colourless, then through sucking filtration or dehydration, then below 80 DEG C, carry out drying, namely obtain Radix Et Rhizoma Fagopyri Tatarici total flavonoids.The yield of gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids is 80 ~ 90%, and wherein the content of rutin accounts for 85 ~ 90% of flavone total amount.
Described Gynostemma Pentaphyllum is obtained by following each step:
A, get Herb Gynostemmae Pentaphylli decontamination, then the aqueous slkali adding Herb Gynostemmae Pentaphylli weight 10 ~ 15 times carries out heating decoction 60 ~ 90 minutes, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution I;
B, add Herb Gynostemmae Pentaphylli weight 7 ~ 10 times of water carry out heating decoction 40 ~ 60 minutes in the remaining filtering residue of step a, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution II;
C, by step a gained extracting solution I and step b gained extracting solution II with the flow velocity of 1 ~ 2 times of resin column volume per hour, successively by efficient D type macroporous adsorptive resins; Use pure water eluting impurity again, to water lotion, molish reaction is for stopping washing time negative, then with resin column 2 times of volumes, concentration is the alcohol flushing resin post of 15 ~ 20v/v%, finally with resin column volume 5 ~ 6 times, concentration is that the ethanol of 70 ~ 80v/v% carries out eluting, collect the ethanol elution of 70 ~ 80v/v%, to reclaim after ethanol through concentrated, crystallize and/or spraying dry, obtain Gynostemma Pentaphyllum.
The aqueous slkali of described step a is the sodium hydroxide solution of pH=8 ~ 9.
The efficient D type macroporous adsorptive resins of described step c is HPD-100 ~ 200 type macroporous adsorptive resins.
The advantage that the present invention possesses and effect: gained Radix Et Rhizoma Fagopyri Tatarici total flavones of the present invention and Gynostemma Pentaphyllum compound have good health protection and therapeutic action to cardiovascular diseases and glycosuria patient, can obviously reduce blood fat and blood glucose.Because the present composition has cooperative effect, so significantly curative effect can be promoted, present good gone out improvement myocardial ischemia, improve myocardial metabolism, cardiac nutrition, protecting myocardial cell, raising cardiac muscle antioxidative ability.Not only compositions treatment drug effect is better than single medicine but also reduces the dual function of dosage, is conducive to alleviating the side effect that prolonged application medicine produces human body, raising drug safety.Compositions better efficacy of the present invention, to have no side effect.
Detailed description of the invention
Below by embodiment, the present invention will be further described.
Embodiment 1
Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound, be made up of the component of following masses part:
Radix Et Rhizoma Fagopyri Tatarici total flavonoids 1 part,
Gynostemma Pentaphyllum 2 parts,
Vitamin E 1 part,
Adjuvant 15 parts.
Described adjuvant forms by the component of following mass parts:
Starch 50 parts,
Microcrystalline Cellulose 10 parts,
Magnesium stearate 0.5 part.
Described Radix Et Rhizoma Fagopyri Tatarici total flavonoids is obtained by following each step:
(1) bran of Radix Et Rhizoma Fagopyri Tatarici being added 8 volumes concentration is doubly that the ethanol of 45v/v% carries out heating and refluxing extraction 4 hours, leaches extracting solution I; In residue, add 4 volumes concentration doubly is again that the ethanol of 35v/v% carries out heating and refluxing extraction 1 hour, leaches extracting solution II; In residue, add 7 quality water doubly again carry out heating and refluxing extraction 1.5 hours, leach extracting solution III; Merge extractive liquid, I and extracting solution II obtain extracting solution IV;
(2) by step (1) gained extracting solution IV and extracting solution III filtered while hot respectively, gained filtrate often pushes back receipts ethanol respectively, then places partial crystallization after concentrating respectively, leaches crystal and namely obtains Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product;
(3) in step (2) gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product, the ethanol that concentration is 80v/v% is added, be heated to boiling again, keep micro-to boil 3 minutes, then filter while hot, then filtrate is placed partial crystallization, until precipitation total flavones, then deionized water wash total flavones is used, to eluate color close to time colourless, then through sucking filtration or dehydration, then below 80 DEG C, carry out drying, namely obtain Radix Et Rhizoma Fagopyri Tatarici total flavonoids.In gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids, the content of rutin accounts for 90% of flavone total amount.
Described Gynostemma Pentaphyllum is obtained by following each step:
A, get Herb Gynostemmae Pentaphylli decontamination, then add Herb Gynostemmae Pentaphylli weight 15 times, the sodium hydroxide solution of pH=8 carries out heating decoction 70 minutes, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution I;
B, add Herb Gynostemmae Pentaphylli weight 8 times of water carry out heating decoction 60 minutes in the remaining filtering residue of step a, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution II;
C, by step a gained extracting solution I and step b gained extracting solution II with the flow velocity of 1 ~ 2 times of resin column volume per hour, successively by HPD-100 type macroporous adsorptive resins; Use the impurity such as pure water eluting saccharide again, to water lotion, molish reaction is for stopping washing time negative, then with resin column 2 times of volumes, concentration is the alcohol flushing resin post of 18v/v%, finally with resin column volume 6 times, concentration is that the ethanol of 70v/v% carries out eluting, collect the ethanol elution of 70v/v%, after reclaiming ethanol, warp concentrates and spraying dry, obtains Gynostemma Pentaphyllum.
Above-mentioned Radix Et Rhizoma Fagopyri Tatarici total flavonoids, Gynostemma Pentaphyllum fully mix in proportion, then add pharmaceutically acceptable adjuvant and be prepared into the conventional oral formulations of any one, as capsule, granule, oral liquid, pill or tablet.
Embodiment 2
Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound, be made up of the component of following masses part:
Radix Et Rhizoma Fagopyri Tatarici total flavonoids 1.5 parts,
Gynostemma Pentaphyllum 3 parts,
Vitamin E 2 parts,
Adjuvant 10 parts.
Described adjuvant forms by the component of following mass parts:
Starch 40 parts,
Microcrystalline Cellulose 15 parts,
Magnesium stearate 0.8 part.
Described Radix Et Rhizoma Fagopyri Tatarici total flavonoids is obtained by following each step:
(1) bran of Radix Et Rhizoma Fagopyri Tatarici being added 6 volumes concentration is doubly that the ethanol of 55v/v% carries out heating and refluxing extraction 2 hours, leaches extracting solution I; In residue, add 6 volumes concentration doubly is again that the ethanol of 30v/v% carries out heating and refluxing extraction 2 hours, leaches extracting solution II; In residue, add 5 quality water doubly again carry out heating and refluxing extraction 0.5 hour, leach extracting solution III; Merge extractive liquid, I and extracting solution II obtain extracting solution IV;
(2) by step (1) gained extracting solution IV and extracting solution III filtered while hot respectively, gained filtrate often pushes back receipts ethanol respectively, then places partial crystallization after concentrating respectively, leaches crystal and namely obtains Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product;
(3) in step (2) gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product, the ethanol that concentration is 80v/v% is added, be heated to boiling again, keep micro-to boil 1 minute, then filter while hot, then filtrate is placed partial crystallization, until precipitation total flavones, then pure water total flavones is used, to eluate color close to time colourless, then through sucking filtration or dehydration, then below 80 DEG C, carry out drying, namely obtain Radix Et Rhizoma Fagopyri Tatarici total flavonoids.In gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids, the content of rutin accounts for 85% of flavone total amount.
Described Gynostemma Pentaphyllum is obtained by following each step:
A, get Herb Gynostemmae Pentaphylli decontamination, then add Herb Gynostemmae Pentaphylli weight 12 times, the sodium hydroxide solution of pH=8.5 carries out heating decoction 60 minutes, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution I;
B, add Herb Gynostemmae Pentaphylli weight 10 times of water carry out heating decoction 40 minutes in the remaining filtering residue of step a, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution II;
C, by step a gained extracting solution I and step b gained extracting solution II with the flow velocity of 2 times of resin column volumes per hour, successively by HPD-200 type macroporous adsorptive resins; Use the impurity such as pure water eluting saccharide again, to water lotion, molish reaction is for stopping washing time negative, then with resin column 2 times of volumes, concentration is the alcohol flushing resin post of 20v/v%, finally with resin column volume 5.7 times, concentration is that the ethanol of 80v/v% carries out eluting, collect the ethanol elution of 80v/v%, through crystallize and spraying dry after recovery ethanol, obtain Gynostemma Pentaphyllum.
Above-mentioned Radix Et Rhizoma Fagopyri Tatarici total flavonoids, Gynostemma Pentaphyllum fully mix in proportion, then add pharmaceutically acceptable adjuvant and be prepared into the conventional oral formulations of any one, as capsule, granule, oral liquid, pill or tablet.
Embodiment 3
Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound, be made up of the component of following masses part:
Radix Et Rhizoma Fagopyri Tatarici total flavonoids 2 parts,
Gynostemma Pentaphyllum 4 parts,
Vitamin E 3 parts,
Adjuvant 20 parts.
Described adjuvant forms by the component of following mass parts:
Starch 45 parts,
Microcrystalline Cellulose 12 parts,
Magnesium stearate 1 part.
Described Radix Et Rhizoma Fagopyri Tatarici total flavonoids is obtained by following each step:
(1) bran of Radix Et Rhizoma Fagopyri Tatarici being added 5 volumes concentration is doubly that the ethanol of 50v/v% carries out heating and refluxing extraction 3 hours, leaches extracting solution I; In residue, add 5 volumes concentration doubly is again that the ethanol of 32v/v% carries out heating and refluxing extraction 3 hours, leaches extracting solution II; In residue, add 4 quality water doubly again carry out heating and refluxing extraction 1 hour, leach extracting solution III; Merge extractive liquid, I and extracting solution II obtain extracting solution IV;
(2) by step (1) gained extracting solution IV and extracting solution III filtered while hot respectively, gained filtrate often pushes back receipts ethanol respectively, then places partial crystallization after concentrating respectively, leaches crystal and namely obtains Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product;
(3) in step (2) gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product, the ethanol that concentration is 80v/v% is added, be heated to boiling again, keep micro-to boil 2 minutes, then filter while hot, then filtrate is placed partial crystallization, until precipitation total flavones, then pure water total flavones is used, to eluate color close to time colourless, then through sucking filtration or dehydration, then below 80 DEG C, carry out drying, namely obtain Radix Et Rhizoma Fagopyri Tatarici total flavonoids.In gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids, the content of rutin accounts for 87% of flavone total amount.
Described Gynostemma Pentaphyllum is obtained by following each step:
A, get Herb Gynostemmae Pentaphylli decontamination, then add Herb Gynostemmae Pentaphylli weight 10 times, the sodium hydroxide solution of pH=9 carries out heating decoction 90 minutes, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution I;
B, add Herb Gynostemmae Pentaphylli weight 7 times of water carry out heating decoction 45 minutes in the remaining filtering residue of step a, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution II;
C, by step a gained extracting solution I and step b gained extracting solution II with the flow velocity of 1 times of resin column volume per hour, successively by HPD-100 type macroporous adsorptive resins; Use the impurity such as pure water eluting saccharide again, to water lotion, molish reaction is for stopping washing time negative, then with resin column 2 times of volumes, concentration is the alcohol flushing resin post of 15v/v%, finally with resin column volume 5 times, concentration is that the ethanol of 75v/v% carries out eluting, collect the ethanol elution of 75v/v%, after reclaiming ethanol, warp is concentrated, obtains Gynostemma Pentaphyllum.
Above-mentioned Radix Et Rhizoma Fagopyri Tatarici total flavonoids, Gynostemma Pentaphyllum fully mix in proportion, then add pharmaceutically acceptable adjuvant and be prepared into the conventional oral formulations of any one, as capsule, granule, oral liquid, pill or tablet.
Get above-described embodiment gained Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound, for following health therapy:
One, treatment target
50 Cases of Diabetes; Hypertension 50 example; Hyperlipidemia 50 example; Have a low resistance 50 example; Coronary heart disease 50 example.
Above-mentioned all kinds of case is divided equally at random for treatment group and each 125 examples of matched group.
Two, usage
Treatment group takes above-described embodiment gained capsule, containing Radix Et Rhizoma Fagopyri Tatarici total flavonoids 20mg, Gynostemma Pentaphyllum 20mg in every, one time 2 ~ 3,3 times on the one, serve on 60 and observe.
Matched group takes the compound preparation of Folium Crataegi total flavones and Quinquefolium saponin, containing Folium Crataegi total flavones and Quinquefolium saponin 90mg altogether in every, one time 2 ~ 3,3 times on the one, serve on 60 and observe.
Three, result
Compound clinical effectiveness provided by the invention: obvious effective rate reaches 100%, reaches 85% to diabetes effective percentage; 90% is reached to hypertension effective percentage; 88% is reached to hyperlipidemia effective percentage; To having a low resistance, effective percentage reaches 92%; 86% is reached to coronary heart disease effective percentage.
And matched group reaches 65% to diabetes effective percentage; 63% is reached to hypertension effective percentage; 37% is reached to hyperlipidemia effective percentage; To having a low resistance, effective percentage reaches 70%; 59% is reached to coronary heart disease effective percentage.
Four, conclusion
Radix Et Rhizoma Fagopyri Tatarici total flavones provided by the invention and Gynostemma Pentaphyllum compound are rich in rutin, the Quercetin of glycosides, ginsenoside's constituents have good health protection and therapeutic action to cardiovascular diseases and glycosuria patient, can obviously reduce blood fat and blood glucose.Because the present composition has cooperative effect, so significantly curative effect can be promoted, present good gone out improvement myocardial ischemia, improve myocardial metabolism, cardiac nutrition, protecting myocardial cell, raising cardiac muscle antioxidative ability.Its therapeutical effect is better than the matched group of current therapies.
This Radix Et Rhizoma Fagopyri Tatarici total flavones and Gynostemma Pentaphyllum compound utilize plant extract purification completely, the advantages such as raw material easily obtains, and application safety, toxic and side effects are little, and obtained constant product quality is easy to use, without any side effects.
Claims (6)
1. Radix Et Rhizoma Fagopyri Tatarici total flavones and a Gynostemma Pentaphyllum compound, is characterized in that being made up of the component of following masses part:
Radix Et Rhizoma Fagopyri Tatarici total flavonoids 1 ~ 2 part,
Gynostemma Pentaphyllum 2 ~ 4 parts,
Vitamin E 1 ~ 3 part,
Adjuvant 10 ~ 20 parts.
2. Radix Et Rhizoma Fagopyri Tatarici total flavones according to claim 1 and Gynostemma Pentaphyllum compound, is characterized in that: described adjuvant forms by the component of following mass parts:
Starch 40 ~ 50 parts,
Microcrystalline Cellulose 10 ~ 15 parts,
Magnesium stearate 0.5 ~ 1 part.
3. Radix Et Rhizoma Fagopyri Tatarici total flavones according to claim 1 and Gynostemma Pentaphyllum compound, is characterized in that: described Radix Et Rhizoma Fagopyri Tatarici total flavonoids is obtained by following each step:
(1) bran of Radix Et Rhizoma Fagopyri Tatarici being added 5 ~ 8 volumes concentration is doubly that the ethanol of 45 ~ 55v/v% carries out heating and refluxing extraction 2 ~ 4 hours, leaches extracting solution I; In residue, add 4 ~ 6 volumes concentration doubly is again that the ethanol of 30 ~ 35v/v% carries out heating and refluxing extraction 1 ~ 3 hour, leaches extracting solution II; In residue, add 4 ~ 7 quality water doubly again carry out heating and refluxing extraction 0.5 ~ 1.5 hour, leach extracting solution III; Merge extractive liquid, I and extracting solution II obtain extracting solution IV;
(2) by step (1) gained extracting solution IV and extracting solution III filtered while hot respectively, gained filtrate often pushes back receipts ethanol respectively, then places partial crystallization after concentrating respectively, leaches crystal and namely obtains Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product;
(3) in step (2) gained Radix Et Rhizoma Fagopyri Tatarici total flavonoids crude product, the ethanol that concentration is 80v/v% is added, be heated to boiling again, keep micro-to boil 1 ~ 3 minute, then filter while hot, then filtrate is placed partial crystallization, until precipitation total flavones, then with deionized water or pure water total flavones, to eluate color close to time colourless, then through sucking filtration or dehydration, then below 80 DEG C, carry out drying, namely obtain Radix Et Rhizoma Fagopyri Tatarici total flavonoids.
4. Radix Et Rhizoma Fagopyri Tatarici total flavones according to claim 1 and Gynostemma Pentaphyllum compound, is characterized in that: described Gynostemma Pentaphyllum is obtained by following each step:
A, get Herb Gynostemmae Pentaphylli decontamination, then the aqueous slkali adding Herb Gynostemmae Pentaphylli weight 10 ~ 15 times carries out heating decoction 60 ~ 90 minutes, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution I;
B, add Herb Gynostemmae Pentaphylli weight 7 ~ 10 times of water carry out heating decoction 40 ~ 60 minutes in the remaining filtering residue of step a, then through filtering, filtrate is concentrated into 1/4 volume and leaves standstill, getting supernatant is extracting solution II;
C, by step a gained extracting solution I and step b gained extracting solution II with the flow velocity of 1 ~ 2 times of resin column volume per hour, successively by efficient D type macroporous adsorptive resins; Use pure water eluting impurity again, to water lotion, molish reaction is for stopping washing time negative, then with resin column 2 times of volumes, concentration is the alcohol flushing resin post of 15 ~ 20v/v%, finally with resin column volume 5 ~ 6 times, concentration is that the ethanol of 70 ~ 80v/v% carries out eluting, collect the ethanol elution of 70 ~ 80v/v%, to reclaim after ethanol through concentrated, crystallize and/or spraying dry, obtain Gynostemma Pentaphyllum.
5. Radix Et Rhizoma Fagopyri Tatarici total flavones according to claim 4 and Gynostemma Pentaphyllum compound, is characterized in that: the aqueous slkali of described step a is the sodium hydroxide solution of pH=8 ~ 9.
6. Radix Et Rhizoma Fagopyri Tatarici total flavones according to claim 4 and Gynostemma Pentaphyllum compound, is characterized in that: described step efficient D type macroporous adsorptive resins is just HPD-100 ~ 200 type macroporous adsorptive resins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626969.XA CN104398677B (en) | 2014-11-10 | 2014-11-10 | A kind of tartary buckwheat general flavone and Gynostemma Pentaphyllum compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626969.XA CN104398677B (en) | 2014-11-10 | 2014-11-10 | A kind of tartary buckwheat general flavone and Gynostemma Pentaphyllum compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104398677A true CN104398677A (en) | 2015-03-11 |
| CN104398677B CN104398677B (en) | 2018-11-16 |
Family
ID=52636386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626969.XA Active CN104398677B (en) | 2014-11-10 | 2014-11-10 | A kind of tartary buckwheat general flavone and Gynostemma Pentaphyllum compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104398677B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112293742A (en) * | 2020-11-02 | 2021-02-02 | 哈工大机器人南昌智能制造研究院 | Blood fat reducing tablet containing tartary buckwheat flavone and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095245A (en) * | 1993-12-08 | 1994-11-23 | 蔡定彪 | A kind of preparation technology of canned gynostemma pentaphyllum drink |
| CN1517358A (en) * | 2003-01-16 | 2004-08-04 | 北京大学安康药物研究院 | Preparation method of gynostemma pentaphylia total saponin |
| CN1517359A (en) * | 2003-01-16 | 2004-08-04 | 北京大学安康药物研究院 | Preparation method of gynostemma pentaphylia total saponin |
| CN101062114A (en) * | 2007-05-28 | 2007-10-31 | 山西省农业科学院农产品综合利用研究所 | Method for distilling flavone from tartary buckwheat bran |
| WO2012110017A1 (en) * | 2011-02-16 | 2012-08-23 | Thanares GmbH | Dietetic or pharmaceutical preparation containing tartary buckwheat |
| CN104000865A (en) * | 2014-06-13 | 2014-08-27 | 沈阳农业大学 | Taurine compound preparation with blood fat reducing function and blood sugar reducing function |
| CN104026304A (en) * | 2014-05-30 | 2014-09-10 | 张家界金鲵生物工程股份有限公司 | Giant salamander and bitter buckwheat tea and preparation method thereof |
-
2014
- 2014-11-10 CN CN201410626969.XA patent/CN104398677B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095245A (en) * | 1993-12-08 | 1994-11-23 | 蔡定彪 | A kind of preparation technology of canned gynostemma pentaphyllum drink |
| CN1517358A (en) * | 2003-01-16 | 2004-08-04 | 北京大学安康药物研究院 | Preparation method of gynostemma pentaphylia total saponin |
| CN1517359A (en) * | 2003-01-16 | 2004-08-04 | 北京大学安康药物研究院 | Preparation method of gynostemma pentaphylia total saponin |
| CN101062114A (en) * | 2007-05-28 | 2007-10-31 | 山西省农业科学院农产品综合利用研究所 | Method for distilling flavone from tartary buckwheat bran |
| WO2012110017A1 (en) * | 2011-02-16 | 2012-08-23 | Thanares GmbH | Dietetic or pharmaceutical preparation containing tartary buckwheat |
| CN104026304A (en) * | 2014-05-30 | 2014-09-10 | 张家界金鲵生物工程股份有限公司 | Giant salamander and bitter buckwheat tea and preparation method thereof |
| CN104000865A (en) * | 2014-06-13 | 2014-08-27 | 沈阳农业大学 | Taurine compound preparation with blood fat reducing function and blood sugar reducing function |
Non-Patent Citations (1)
| Title |
|---|
| 谭文等: "绞股蓝皂苷提取工艺的研究", 《农业科技》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112293742A (en) * | 2020-11-02 | 2021-02-02 | 哈工大机器人南昌智能制造研究院 | Blood fat reducing tablet containing tartary buckwheat flavone and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104398677B (en) | 2018-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101912484B (en) | Chinese medicinal composition for treating hypertension, hyperlipidemia and hyperglycemia | |
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN105920067A (en) | Sunflower calathide extract containing polysaccharide, flavonoid and alkaloid and preparation method of sunflower calathide extract | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| CN103223016B (en) | Ginseng, mulberry leaf and chicoric acid composition for treating diabetes | |
| CN101172155A (en) | Novel dosage forms of pulse-activating gallbladder warming soup and method of preparing the same | |
| CN101933965A (en) | Mugwort extract and preparation process thereof, and application in controlling postmeal gucose | |
| CN104083438A (en) | Balsam pear-containing traditional Chinese medicinal preparation for alleviating hypertension, and preparation method thereof | |
| CN101297823A (en) | Medicament for preventing and treating Alzheimer's disease | |
| CN101904891B (en) | Ginkgo leaf pills and preparation method thereof | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN104398677A (en) | Compound composition of tartary buckwheat general flavone and gynostemma pentaphylla total saponin | |
| CN101152223B (en) | Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN103027944A (en) | Pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular disease | |
| CN106138831A (en) | A kind of Chinese medicine composition treating cardiovascular and cerebrovascular disease and preparation method thereof | |
| CN107648335B (en) | Traditional Chinese medicine composition for regulating atherosclerosis autophagy and apoptosis and preparation method thereof | |
| CN102552410B (en) | Preparation method of medicine for treating hypertension disease | |
| CN101745011B (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN101744991B (en) | Single extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
| CN108420842A (en) | A kind of sowthistle-leaf ixeris seedling preparation of antigout effect | |
| CN102772665B (en) | Traditional Chinese medicine preparation for treating yin deficiency and internal heat type vital myocarditis and preparation method thereof | |
| CN106309616A (en) | Medicine with hypolipidemic effect | |
| CN105663224A (en) | Composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |